Equities research analysts predict that PolarityTE, Inc. (NASDAQ:PTE – Get Rating) will post $810,000.00 in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for PolarityTE’s earnings, with the lowest sales estimate coming in at $730,000.00 and the highest estimate coming in at $900,000.00. PolarityTE posted sales of $2.54 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 68.1%. The company is scheduled to announce its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that PolarityTE will report full year sales of $3.21 million for the current year, with estimates ranging from $2.82 million to $3.60 million. For the next financial year, analysts anticipate that the company will report sales of $3.15 million, with estimates ranging from $2.50 million to $3.80 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow PolarityTE.
PolarityTE (NASDAQ:PTE – Get Rating) last released its quarterly earnings data on Monday, May 16th. The company reported ($2.50) EPS for the quarter, missing the consensus estimate of ($2.00) by ($0.50). PolarityTE had a negative net margin of 304.42% and a negative return on equity of 132.71%. During the same quarter in the previous year, the company earned ($3.00) earnings per share.
PTE opened at $2.30 on Thursday. The firm has a fifty day moving average price of $6.19 and a 200 day moving average price of $9.87. PolarityTE has a 1 year low of $2.16 and a 1 year high of $29.50. The stock has a market cap of $9.20 million, a P/E ratio of -0.37 and a beta of 1.13.
Large investors have recently bought and sold shares of the business. Marshall Wace North America L.P. acquired a new stake in shares of PolarityTE in the first quarter valued at about $73,000. Marshall Wace LLP acquired a new stake in shares of PolarityTE in the first quarter valued at about $126,000. First Republic Investment Management Inc. raised its position in shares of PolarityTE by 79.1% in the third quarter. First Republic Investment Management Inc. now owns 56,600 shares of the company’s stock valued at $37,000 after buying an additional 25,000 shares during the last quarter. HighTower Advisors LLC acquired a new stake in shares of PolarityTE in the fourth quarter valued at about $35,000. Finally, D. E. Shaw & Co. Inc. raised its position in shares of PolarityTE by 188.6% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 76,867 shares of the company’s stock valued at $45,000 after buying an additional 50,236 shares during the last quarter. Institutional investors own 11.14% of the company’s stock.
About PolarityTE (Get Rating)
PolarityTE, Inc, a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services.
- Get a free copy of the StockNews.com research report on PolarityTE (PTE)
- The Analysts Like The Fit Of Victoria’s Secret & Co
- Ambarella Is A Buy For Patient Investors
- Don’t Bet On A Big Rebound For Salesforce.com Stock
- 3 Specialty Retailers with Special Upside
- Is Roku (NASDAQ: ROKU) Bottoming Out?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PolarityTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolarityTE and related companies with MarketBeat.com's FREE daily email newsletter.